amiodarone has been researched along with Cardiac Conduction Defect in 5 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cardiac disorders caused by sofosbuvir are liable to be worsened by concomitant use of one of the many drugs that provoke cardiac arrhythmia." | 7.81 | Sofosbuvir + amiodarone: bradycardia and conduction disturbances. ( , 2015) |
| "Cardiac disorders caused by sofosbuvir are liable to be worsened by concomitant use of one of the many drugs that provoke cardiac arrhythmia." | 3.81 | Sofosbuvir + amiodarone: bradycardia and conduction disturbances. ( , 2015) |
| "Although amiodarone appears to have few pro-arrhythmic effects, torsade de pointes (TdP) has been observed after administration of a low dose and short term use of oral amiodarone, in the absence of predisposing factors." | 3.80 | Intermittent QT prolongation induced by short-term oral amiodarone therapy. ( Amasyalı, B; Astarcioglu, MA; Durmuş, HI; Sen, T, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| DeFilippis, EM | 1 |
| Batra, J | 1 |
| Donald, E | 1 |
| Rubin, G | 1 |
| Jou, S | 1 |
| Razzaq, A | 1 |
| Wan, EY | 1 |
| Garan, H | 1 |
| Takeda, K | 1 |
| Sayer, G | 1 |
| Uriel, N | 1 |
| Topkara, VK | 1 |
| Biviano, A | 1 |
| Yarmohammadi, H | 1 |
| Beserra, SS | 1 |
| Santos-Miranda, A | 1 |
| Sarmento, JO | 1 |
| Miranda, VM | 1 |
| Roman-Campos, D | 1 |
| Astarcioglu, MA | 1 |
| Durmuş, HI | 1 |
| Sen, T | 1 |
| Amasyalı, B | 1 |
| Zhang, X | 1 |
| Beebe, T | 1 |
| Jen, N | 1 |
| Lee, CA | 1 |
| Tai, Y | 1 |
| Hsiai, TK | 1 |
5 other studies available for amiodarone and Cardiac Conduction Defect
| Article | Year |
|---|---|
Long-Term Outcomes of Permanent Pacemaker Implantation in Bicaval Heart Transplant Recipients.
Topics: Amiodarone; Cardiac Conduction System Disease; Heart Transplantation; Hematoma; Humans; Pacemaker, A | 2023 |
Effects of amiodarone on rodent ventricular cardiomyocytes: Novel perspectives from a cellular model of Long QT Syndrome Type 3.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Cardiac Conduction System Disease; Dose-Response Relati | 2020 |
Intermittent QT prolongation induced by short-term oral amiodarone therapy.
Topics: Administration, Oral; Adult; Amiodarone; Anti-Arrhythmia Agents; Brugada Syndrome; Cardiac Conductio | 2014 |
Flexible and waterproof micro-sensors to uncover zebrafish circadian rhythms: The next generation of cardiac monitoring for drug screening.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biosensing Techniques; Brugada Sy | 2015 |
Sofosbuvir + amiodarone: bradycardia and conduction disturbances.
Topics: Amiodarone; Anti-Arrhythmia Agents; Antiviral Agents; Arrhythmias, Cardiac; Bradycardia; Brugada Syn | 2015 |